Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

213
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
213
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

291
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
291
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

591
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
591
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

259
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
259
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

9.7K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
9.7K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

Cancers·2026
Same author

Superior accuracy of a novel multidimensional index integrating static and dynamic liver stiffness for hepatocellular carcinoma risk prediction in chronic hepatitis B.

Journal of medical ultrasonics (2001)·2026
Same author

A multicenter randomized controlled trial comparing metallic stents with 10- versus 14-mm diameter for distal biliary obstruction caused by unresectable pancreatic carcinoma.

Gastrointestinal endoscopy·2026
Same author

Disease-specific gut microbial signatures generate model-derived cancer probability scores through targeted fecal qPCR profiling.

Bioscience, biotechnology, and biochemistry·2026
Same author

Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis.

Oncology·2026
Same author

Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab.

Anticancer research·2026

Related Experiment Video

Updated: Feb 19, 2026

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

17.0K

Increase in Albumin by Daclatasvir/asunaprevir Therapy is Correlated with Decrease in Aspartate Transaminase.

Toshiki Kan1, Senju Hashimoto1, Naoto Kawabe1

  • 1Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University, Aichi470-1192, Japan.

Journal of Translational Internal Medicine
|November 1, 2017
PubMed
Summary

Daclatasvir/asunaprevir therapy increased albumin levels in chronic hepatitis C patients with sustained virologic response (SVR). This rise was linked to reduced inflammation and aspartate transaminase levels, not fibrosis reduction.

Keywords:
albuminaspartate transaminaseasunaprevircirrhosisdaclatasvirhepatitis C virusinflammationsustained virological response

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.7K
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K

Related Experiment Videos

Last Updated: Feb 19, 2026

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
12:27

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt

Published on: May 7, 2015

17.0K
An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.7K
Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
07:38

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Published on: May 6, 2018

8.9K

Area of Science:

  • Hepatology
  • Virology
  • Biochemistry

Background:

  • Chronic hepatitis C virus (HCV) infection can lead to liver dysfunction.
  • Albumin levels are a key indicator of liver synthetic function.
  • Daclatasvir (DCV)/asunaprevir (ASV) is a direct-acting antiviral regimen for HCV.

Purpose of the Study:

  • To investigate the mechanism behind increased albumin levels observed during DCV/ASV therapy.
  • To identify factors associated with albumin level elevation in HCV patients undergoing DCV/ASV treatment.

Main Methods:

  • Retrospective analysis of 125 chronic hepatitis C patients treated with DCV/ASV.
  • Assessment of albumin and aspartate transaminase (AST) levels at baseline and 24 weeks post-treatment.
  • Multivariate analysis to identify factors correlated with albumin increase.

Main Results:

  • Albumin levels significantly increased in patients achieving sustained virologic response (SVR) post-DCV/ASV therapy.
  • Greater albumin level increases were observed in patients with lower baseline albumin levels.
  • A decrease in AST levels was the sole factor associated with a significant albumin increase, suggesting inflammation reduction.

Conclusions:

  • DCV/ASV therapy effectively increases albumin levels in SVR patients.
  • The rise in albumin is primarily attributed to reduced liver inflammation, not amelioration of fibrosis.
  • The correlation between increased albumin and decreased AST highlights the impact of antiviral therapy on liver health markers.